Abstract-We recently reported that leukemia inhibitory factor (LIF) enhances Ca 2ϩ ] i through an increase in L-type Ca 2ϩ current (I Ca,L ) in adult cardiomyocytes. The aim of this study was to investigate whether LIF activates Ca 2ϩ -dependent signaling molecules, such as calcineurin and calmodulin kinases II and IV (CaMKII and CaMKIV), and, if so, whether these Ca 2ϩ -mediated signaling events contribute to LIF-mediated cardiac hypertrophy. We first confirmed that LIF increased I Ca,L and [Ca 2ϩ ] i in primary cultured rat neonatal cardiomyocytes. Calcineurin, CaMKII, and CaMKIV activities increased at 2 minutes and peaked by 1.6-, 2.2-, and 2.2-fold, respectively, at 15 minutes. Nicardipine or verapamil fully inhibited these activities. Autophosphorylation of CaMKII was also observed to parallel the timing of CaMKII activity, and this phosphorylation was blocked by nicardipine, verapamil, or EGTA. LIF treatment led to a 3-fold increase in nuclear factor of activated T cell-luciferase activity. To confirm that inositol triphosphate (IP 3 )-induced Ca 2ϩ release from sarcoplasmic reticulum was not involved in this process, IP 3 content and phosphorylation of phospholipase C␥ were investigated. LIF did not increase IP 3 content or phosphorylate phospholipase C␥. KN62 (an inhibitor of CaMKII and CaMKIV) attenuated c-fos, brain natriuretic peptide, ␣-skeletal actin, and atrial natriuretic peptide expression. KN62 suppressed the LIF-induced increase in Key Words: leukemia inhibitory factor Ⅲ calcium Ⅲ calmodulin-dependent kinase Ⅲ calcineurin Ⅲ cardiac hypertrophy L eukemia inhibitory factor (LIF), a member of the interleukin-6 family of cytokines, has a potent hypertrophic effect on cardiomyocytes. However, the underlying molecular mechanisms that couple hypertrophic signals initiated at the cell membrane receptor to the reprogramming of cardiomyocyte gene expression remain poorly understood. We and others have demonstrated that the Janus kinase and signal transducers and activators of transcription pathway, mitogen-activated protein kinase (MAPK) pathway, and phosphatidyl inositol 3 (PI3) kinase pathway were present downstream of gp130 in cardiomyocytes. ] i transient took a unique time course, which gradually increased from 2 minutes and peaked at 15 minutes. Moreover, although the precise mechanism remains unknown, these increases were not mediated by protein kinase A (PKA) or protein kinase C (PKC) pathways.
L eukemia inhibitory factor (LIF), a member of the interleukin-6 family of cytokines, has a potent hypertrophic effect on cardiomyocytes. However, the underlying molecular mechanisms that couple hypertrophic signals initiated at the cell membrane receptor to the reprogramming of cardiomyocyte gene expression remain poorly understood. We and others have demonstrated that the Janus kinase and signal transducers and activators of transcription pathway, mitogen-activated protein kinase (MAPK) pathway, and phosphatidyl inositol 3 (PI3) kinase pathway were present downstream of gp130 in cardiomyocytes. [1] [2] [3] [4] We recently reported that LIF enhanced L-type Ca 2ϩ current by 42% and [Ca 2ϩ ] i transient by 63% in cardiomyocytes. 5 Interestingly, LIF-induced increases in L-type Ca 2ϩ current and [Ca 2ϩ ] i transient took a unique time course, which gradually increased from 2 minutes and peaked at 15 minutes. Moreover, although the precise mechanism remains unknown, these increases were not mediated by protein kinase A (PKA) or protein kinase C (PKC) pathways.
There is a growing body of evidence to suggest that Ca 2ϩ signaling plays an important role in the pathogenesis of cardiac hypertrophy and heart failure. Recently, the Ca 2ϩ / calmodulin-dependent protein phosphatase calcineurin has attracted attention as a new signal transducer of hypertrophic stimuli in vitro and in vivo. Calcineurin dephosphorylates the nuclear factor of activated T cells (NFAT)-3 transcription factor, which is then translocated into the nucleus. Recently, Molkentin et al 6 reported that NFAT-3, GATA-4, and calcineurin synergistically activate a marker gene of cardiac hypertrophy. In cultured cardiomyocytes, cyclosporin A (CsA), an inhibitor of calcineurin activity, inhibited angiotensin II-induced and phenylephrine-induced cardiac hypertrophy. Cardiac overexpression of the constitutively active form of calcineurin and NFAT-3 caused marked hypertrophy and heart failure in transgenic mice, which was blocked by CsA. Sussman et al 7 reported that CsA and FK506 prevent cardiac hypertrophy attributable to genetic perturbations in contractile proteins in hypertrophic cardiomyopathy model mice. However, they also reported that these blockers did not block hypertrophy attributable to overexpression of the constitutively active form of retinoic acid receptor. 7 Moreover, the effects of CsA and FK506 remain controversial in pressure-overloaded cardiac hypertrophy models. 8 -12 Thus, it remains to be determined whether the calcineurin pathway is universally implicated in cardiac hypertrophy in response to all kinds of hypertrophic stimuli.
Calmodulin-dependent kinase II (CaMKII) is an intracellular enzyme that was discovered several years ago in the brain. CaMKII is known to have several isoforms (␣ to ␦), and the gene products are additionally divided into splicing variants. 13 All ␣ and ␤ isoforms are found only in the brain, with the exception of the ␥ and ␦ isoforms, which have been detected in rat heart. 14, 15 CaMKII has also been implicated in the transduction of hypertrophic signals in cultured cardiomyocytes. 16 -18 Expression of the ␦B isoform of CaMKII specifically activates atrial natriuretic peptide (ANP) expression without inducing cellular hypertrophy. 19 Recently, Lu et al 20 reported that hypertrophic growth of cardiomyocytes in response to phenylephrine and serum is accompanied by muscle enhancer factor 2 (MEF2) activation through a posttranslational mechanism mediated by CaMKI, CaMKIV, and p38 MAPK, and these CaMKs stimulate MEF2 activity by dissociating class II histone deacetylase from the DNA-binding domain. They concluded that these CaMKs and p38 MAPK-dependent activation of MEF2 were endpoints for the hypertrophic stimuli in cardiomyocytes.
These findings suggested that calcium-regulated signaling molecules play a central regulatory role in coordinating the activities of multiple hypertrophic signaling pathways. On the basis of these findings, we investigated whether LIF activates the calcineurin, CaMKII, and CaMKIV pathways via an increase in I Ca,L and [Ca 2ϩ ] i transient in rat cardiomyocytes, and if so, whether this calcium-regulated signaling is involved in the hypertrophic response induced by LIF.
Materials and Methods

Cell Culture
Primary cultures of cardiomyocytes were prepared from the ventricles of 1-day-old neonatal Wistar rats as described. 1 Cells were stimulated with LIF 1000 U/mL.
Perforated Patch-Clamp Recording
Perforated patch-clamp recording was performed using gramicidin, as described in the online data supplement.
Measurement of the [Ca 2؉ ] i Transient
The [Ca 2ϩ ] i transient was monitored by use of the fluorescent calcium indicator Fluo-4, as described in the online data supplement.
Measurement of CaMKII and CaMKIV Activity
Cells were collected in an assay dilution buffer and lysed by sonication. Anti-CaMKII (Santa Cruz) or CaMKIV (Transduction Laboratory) antibody and protein A Sepharose beads were added to the lysates and incubated overnight at 4°C. CaMKII activity was assayed with CaMKII assay kits (Upstate Biotechnology Inc) using a peptide substrate (KKALRRQETVDAL) according to the manufacturer's instructions. CaMKIV activity was assayed using a peptide substrate (KSDGGVKKRKSSSS).
Measurement of Calcineurin Activity
Calcineurin activity was determined by the protocol of Shibasaki and McKeon, 21 with minor modifications. Cells were lysed in 400 L of lysis buffer and freeze-thawed. After removing of cell debris, lysate was incubated in the assay buffer and [ 32 P]-labeled RII peptide for 30 minutes at 30°C. The released 32 P-phosphate in 500 L of supernatant was determined by Cherenkov's method. Because the phosphatase activity using this assay buffer represents the mixed activity of PP2B and PP2C, we obtained the PP2B (calcineurin) activity by subtracting PP2C activity from the mixture activity. The PP2C activity was measured by a similar method using the same buffer by chelating Ca 2ϩ with 5 mmol/L EGTA.
Immunoprecipitation (IP)-Western Blot Analysis
Antibody to phospholipase C (PLC)-␥ 1 was purchased from Santa Cruz Biolabs. Monoclonal antibody to phosphotyrosine (4G10) was purchased from Chemicon International Inc. IP Western blot was performed as described.
1
Transfection and Luciferase Assay
Transient transfection was performed using Effectene transfection reagent (Qiagen). Within 24 hours after plating, cells were incubated with a transfection mixture with 0.24 g of NFAT-luciferase reporter plasmids, 0.08 g of plasmid encoding the constitutively active form of MEKK1 (Stratagene), and 0.08 g of pRL-SV40 (Promega) as an internal control plasmid. Total cell lysates were collected 6 hour after LIF stimulation, and luciferase activity was measured by Dual Luciferase reporter assay system (Promega).
Radioimmunoassay of Inositol Triphosphate
Radioimmunoassay kit for inositol triphosphate (IP 3 ) was purchased from Amersham Pharmacia. IP 3 content was measured according to the manufacturer's instructions.
Incorporation of [ 3 H]Phenylalanine
The effects of LIF on [ 3 H]phenylalanine uptake were determined as described.
1 After 24 hours of serum depletion, cells were pretreated with or without KN62 or CsA, and then the cells were stimulated with LIF. Each data point was the mean of 5 separate experiments.
Immunofluorescence Microscopy and Cell Sizing Protocol
Cells grown on glass coverslips were permeabilized in cold methanol (1:1, Ϫ20°C) for 10 minutes and air dried. Immunofluorescence staining and measurement of the size (cell area, perimeter) were performed as described previously.
2
RNA Extraction and Northern Blot Analysis
Northern blots were performed as described. 2 Rat ANP and brain natriuretic peptide (BNP) cDNA was obtained by reverse transcriptase-polymerase chain reaction from the heart RNA and cloned into the pCR II plasmid. Rat ␣-skeletal actin cDNA was provided by Hiroshi Ito (Tokyo Medical and Dental University, Tokyo, Japan). Rat GAPDH cDNA was used as an internal control.
Statistical Analysis
Values are presented as meanϮSD. Statistical significance among mean values was evaluated with an ANOVA. Student's t test was used when 2 values were compared. Differences were considered to be significant when PϽ0.05.
An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.
Results
LIF Increased I Ca,L and [Ca 2؉ ] i in Neonatal Rat Cardiomyocytes
Because our previous study used cultured adult rat cardiomyocytes, we first confirmed whether LIF also increases I Ca,L in neonatal rat cardiomyocytes using perforated patch-clamp techniques. Figure 1A 
LIF Activates the CaMKII and CaMKIV Pathways in Cardiomyocytes
To determine whether the LIF-induced increase in [Ca 2ϩ ] transient can augment CaMKII and CaMKIV activities in cardiomyocytes, we initially measured the CaMKII activity in LIF-stimulated cardiomyocytes ( Figure 2A ). CaMKII activity increased from 2 minutes, peaked by 2.2-fold at 15 minutes, and decreased thereafter.
Once CaMKII is activated by the Ca 2ϩ /calmodulin complex, CaMKII is known to autophosphorylate and does not need calmodulin for its activity. To confirm that LIF really activates the CaMKII, we performed IP Western blot analysis to detect the phosphorylation of CaMKII with antiphosphoCaMKII antibody ( Figure 2B ). LIF augmented phosphorylation of CaMKII from 2 minutes, peaked at 15 minutes, and then decreased thereafter.
Next, we measured the CaMKIV activity in LIF-stimulated cells (Figure 3 ). LIF increased CaMKIV from 2 minutes and Effect of LIF on CaMKII activity and autophosphorylation of CaMKII in cardiomyocytes. A, Cardiomyocytes were stimulated with LIF for the indicated times. CaMKII was immunoprecipitated, and its activity was assayed using a synthetic peptide as a substrate. CaMKII activity was increased by 2. 
LIF Activates Calcineurin and NFAT-3 Luciferase Activity in Cardiomyocytes
We measured the calcineurin activity in LIF-stimulated cardiomyocytes ( Figure 4 ). The calcineurin activity increased at 2 minutes, peaked by 1.6-fold at 15 minutes, and decreased thereafter. The time course of the activation of calcineurin corresponded to that of CaMKII and CaMKIV. It is well known that cytosolic NFAT is dephosphorylated by calcineurin and is translocated to the nucleus. NFAT proteins form cooperative DNA-binding complexes with dimers of the activator protein-1 (AP-1) (Fos/Jun) family at composite NFAT:AP-1 DNA elements that have been identified in multiple NFAT-regulated genes, including interleukin-2. To additionally confirm whether LIF activates calcineurin in cardiomyocytes, we examined NFAT transcriptional activity using an NFAT:AP-1 luciferase plasmid derived from interleukin-2 gene promoter. To investigate the activation of the Ca 2ϩ /calcineurin-NFAT pathway elicited by LIF independent of AP-1 activation, we cotransfected an active form of MEKK1, which actives c-Jun N-terminal kinase cascades, to constitutively activate AP-1 activity. In unstimulated cells, FK506-inhibitable NFAT-luciferase activity was observed. LIF increased this NFAT-luciferase activity by 3-fold, and this increase was completely inhibited by CsA ( Figure 4B ). These results suggested that LIF can activate calcineurin, which is in turn sufficient for dephosphorylation and activation of NFAT in cardiomyocytes.
L-Type Ca 2؉ Channel Mediates the LIF-Induced Activation of CaMKII, CaMKIV, and Calcineurin
To confirm that the LIF-induced increase in CaMKII, CaMKIV, and calcineurin activities were caused by Ca 2ϩ -induced Ca 2ϩ release via an L-type Ca 2ϩ current, we preincubated the cells with 10 -6 mol/L nicardipine or 10 -6 mol/L verapamil, stimulated with LIF, and measured CaMKII CaMKIV and calcineurin activities ( Figures 5A through 5C ). KN62 (CaMKII and CaMKIV inhibitor) and CsA were used as a control. KN62 and CsA inhibited the LIF-induced increase in CaMKII and CaMKIV and CN activities, respectively. LIF-induced increase in CaMKII, CaMKIV, and calcineurin activity was almost completely inhibited by nicardipine or verapamil. These results were reproducible in 3 separate experiments. We also observed the effect of nicardipine, verapamil, or EGTA (1 mmol/L) on LIF-induced autophosphorylation of CaMKII. Nicardipine, verapamil, and EGTA fully inhibited this phosphorylation ( Figure 5C ). We additionally examined whether preincubation of nicardipine, verapamil, and EGTA can inhibit LIF-induced autophosphorylation of CaMKII ( Figure 5D ). These reagents strongly inhibited the autophosphorylation of CaMKII. These findings indicated that the L-type Ca 2ϩ currents mediate LIF-induced activation of CaMKII, CaMKIV, and calcineurin.
Next, we examined whether sarcoplasmic reticulum Ca 2ϩ store was involved in the LIF-induced activation of CaMKIV in cardiomyocytes. We preincubated the cells with thapsigargin (1 mol/L) for 8 hours, stimulated with LIF, and measured CaMKIV activity. Thapsigargin completely inhibited LIF-induced increase in CaMKIV activity, and its level was lower than that of the control (data not shown), indicating that the sarcoplasmic reticulum Ca 2ϩ store was involved in LIF-induced activation of CaMKIV. Taken together, these findings indicated that Ca 2ϩ -induced Ca 2ϩ release might be involved in activation of these kinases and phosphatase. Cardiomyocytes were stimulated with LIF for the indicated times. CaMKIV was immunoprecipitated, and its activity was assayed using a synthetic peptide as a substrate. CaMKIV activity was increased by 2.2-fold at 15 minutes. Experiments were repeated 4 times, and the results were reproducible in each experiment. *PϽ0.01. Figure 4 . Effect of LIF on calcineurin and NFAT promoter activity in cardiomyocytes. A, Phosphatase activity of calcineurin was assayed using phosphorylated RII peptide, as described in Materials and Methods. LIF activated calcineurin activity by 1.6-fold at 15 minutes. The experiments were reproducible in 5 separate experiments. B, Cells were incubated with a transfection mixture with NFAT-luciferase reporter plasmids and plasmid encoding the constitutively active form of MEKK1 or pRL-SV40 as an internal control. Luciferase activity was measured as described in Materials and Methods. LIF increased NFATluciferase activity by 3-fold. Ca 2ϩ ionophore A23187 dramatically increased its activity by 89-fold. *PϽ0.01.
Nicardipine and Verapamil Inhibited LIF-Induced Increase in [ 3 H]Phenylalanine Uptake
To confirm that a LIF-induced increase in L-type Ca 2ϩ current was involved in LIF-induced cardiac hypertrophy, we performed [ 3 H]phenylalanine uptake experiments to test whether nicardipine or verapamil can inhibit LIF-induced hypertrophy ( Figure 5E ). The LIF-induced increase in [ 3 H]phenylalanine uptake was significantly attenuated by preincubation of nicardipine and verapamil.
LIF-Induced Activation of CaMKII, CaMKIV, and Calcineurin Was Independent of PLC/IP 3 Pathway
To date, there is no evidence to suggest that the gp130 receptor mediates its signal through the PLC/IP 3 pathway. To confirm that LIF-induced activation of Ca 2ϩ -dependent pathway was not mediated by the PLC/IP 3 pathway, we performed IP Western blot analysis to detect the tyrosine phosphorylation of PLC-␥ 1 . Platelet-derived growth factor (PDGF) was used as a positive control. PDGF strongly phosphorylated PLC-␥ 1 , but LIF did not phosphorylate PLC-␥ 1 ( Figure 6A ). We also confirmed that LIF did not increase IP 3 content in cardiomyocytes ( Figure 6B ). Together, these results indicated that LIF-induced activation of CaMKII, CaMKIV, and calcineurin was mediated not by the PLC/IP 3 pathway but by L-type Ca 2ϩ current-induced Ca 2ϩ release.
Role of CaMKII and CaMKIV in LIF-Induced Cardiac Hypertrophy
To determine whether LIF-induced activation of CaMKII and CaMKIV plays an important role in mediating cardiac hypertrophy, we investigated the effect of KN62 on the LIFinduced increase in [ 3 H]phenylalanine uptake by 78.5%, whereas KN62 at this concentration had no effect on the baseline [ 3 H]phenylalanine uptake ( Figure 7B ). LIF caused a 48% and 27% increase in cell area and perimeter compared with the control cells, respectively. KN-62 (1 mol/L) significantly decreased the LIF-induced increase in cell area and perimeter by 46% and 57%, respectively, whereas KN-62 alone did not significantly attenuate the cell size ( Figures 7C and 7D) . The results were fully reproducible and indicated that the LIF-induced increase in cardiac hypertrophy was partially mediated by CaMKII or CaMKIV.
Role of Calcineurin in LIF-Induced Cardiac Hypertrophy
To investigate the role of calcineurin in LIF-induced cardiac hypertrophy, we also performed the same assay using FK506 or CsA. Northern blotting revealed that both FK506 and CsA did not affect the LIF-induced induction of c-fos, BNP (1 hour), or ANP ( Figure 8A ) expression. Because a previous report found that the promoter sequences of BNP contained NFAT-binding sequences and that calcineurin plays an important role in BNP expression, we additionally analyzed the effect of CsA on LIF-induced induction of the BNP genes. CsA did not affect LIFinduced induction of the BNP gene at 30 minutes; however, it attenuated BNP expression from 2 to 24 hours ( Figure 8B ). CsA inhibited the LIF-induced increase in [ 3 H]phenylalanine uptake by 37% at a concentration of 50 ng/mL ( Figure 8C ). CsA also decreased the LIF-induced increase in cell area and perimeter of the cells by 39% and 46%, respectively, at a concentration of 50 ng/mL ( Figures  8D and 8E ). These findings indicated that calcineurin might be involved in LIF-induced cardiac hypertrophy.
Discussion
In cardiomyocytes, 19 showed that the CaMKII inhibitors M7 and KN93 prevent myocardial hypertrophy and upregulation of ANP in response to phenylephrine, which indicates that CaMKII activation is an essential step in phenylephrinemediated hypertrophy. 22 Abraham et al 27 reported that angiotensin II, vasopressin, and PDGF increased CaMKII activity Lu et al 20 recently suggested the new idea that MEF2 is an endpoint for the hypertrophic stimuli in cardiomyocytes and that MEF2 mediates synergistic transcriptional response to the CaMKs and p38 MAPK signaling pathways by signaldependent dissociation of histone deacetylase. They proposed a model for the regulation of MEF2 by CaMKI and CaMKIV. Hypertrophic signals that activate CaMKI, CaMKIV, and p38 MAPK lead to MEF2 activation by a different mechanism. Some stimuli, such as phenylephrine, may activate both pathways. Association of histone deacetylase 4/5 with the DNA-binding domain of MEF2 represses MEF transcriptional activity. CaMKI and CaMKIV activates MEF2 by preventing association of histone deacetylase 4/5 with MEF2. p38 MAPK stimulates MEF2 by direct phosphorylation of the transcription activation domain. Together, the CaMKs and p38 MAPK pathways synergize to activate MEF2. The present study demonstrated that LIF activated CaMKIV in cardiomyocytes and KN62 inhibited LIF-induced cardiac hypertrophy. Because KN62 can inhibit both CaMKII and CaMKIV, the inhibitory effect of KN62 might be an additive effect of the inhibition of the 2 kinases. We have already confirmed that LIF activated p38 MAPK in cardiomyocytes (data not shown). Our findings indicated that the CaMK-p38 MAPK-MEF2 theory might also play an important role in gp130-mediated cardiac hypertrophy, although this theory is still controversial.
Since Molkentin et al 6 reported that this calcineurin-NFAT3 pathway was critical to the induction of cardiac hypertrophy, several studies of this pathway have been reported. Sussman et al 7 reported that inhibition of this pathway by CsA or FK506 could prevent pressure overloadinduced in vivo cardiac hypertrophy produced by aortic banding. Luo et al, 9 Ding et al, 10 and Zhang et al 11 independently reported that these calcineurin inhibitors did not inhibit pressure overload-induced cardiac hypertrophy, and Meguro et al 12 reported that CsA attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Moreover, Force et al 28 reported that human transplanted heart shows long-term cardiac hypertrophy despite the use of these compounds. CsA and FK506 are well known to cause hypertension in vivo and have several side effects. Thus, it is difficult to conclude that inhibition of this pathway in vivo is sufficient to prevent cardiac hypertrophy. In the present study, we have shown that LIF activated calcineurin in cardiomyocytes and that inhibition of this pathway by CsA or FK506 partially blocked protein synthesis and slightly attenuated BNP expression but did not affect c-fos and ANP expression. On the basis of these findings, we suspect that the calcineurin pathway might well be involved in LIF-induced cardiac hypertrophy.
In conclusion, we have demonstrated for the first time, to our knowledge, that LIF activates CaMKII, CaMKIV, and calcineurin by an increase in I Ca,L . in cardiomyocytes and that CaMKII, CaMKIV, and calcineurin contributed significantly to LIF-induced cardiac hypertrophy in vitro. The importance of the calcineurin/NFAT3 and CaMKIV-MEF2 pathways in cardiac hypertrophy is still controversial, and additional investigation is needed to clarify their role.
